apomorphine has been researched along with 1-(4-bromophenylaminocarbonyl)-4,5-diphenyl-3-pyrazolidinone in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Czachura, JF; Howbert, JJ; Rasmussen, K; Stockton, ME | 1 |
| Burger, JE; Czachura, JF; Gates, MR; Rasmussen, K | 1 |
2 other study(ies) available for apomorphine and 1-(4-bromophenylaminocarbonyl)-4,5-diphenyl-3-pyrazolidinone
| Article | Year |
|---|---|
Cholecystokinin (CCK) and schizophrenia: the selective CCKB antagonist LY262691 decreases midbrain dopamine unit activity.
Topics: Animals; Antipsychotic Agents; Apomorphine; Cholecystokinin; Dopamine; Male; Mesencephalon; Neurons; Pyrazoles; Rats; Rats, Inbred Strains; Schizophrenia | 1991 |
The novel atypical antipsychotic olanzapine, but not the CCK-B antagonist LY288513, blocks apomorphine-induced disruption of pre-pulse inhibition.
Topics: Acoustic Stimulation; Animals; Antipsychotic Agents; Apomorphine; Benzodiazepines; Dose-Response Relationship, Drug; Hormone Antagonists; Male; Olanzapine; Pirenzepine; Pyrazoles; Rats; Reflex, Startle | 1997 |